Advertisement
Aortic valve replacement is best option for lowering mortality in this high-risk population
Large longitudinal study supports earlier intervention over clinical surveillance
Support for a TAVR-first approach in patients with concurrent valve and coronary disease
Five-year data demonstrate convergence of outcomes from years 1 to 5
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Randomized WATCH-TAVR trial confirms safety of the combined procedures
Differences in pace of hemodynamic change signal need for sex-specific management
Potential benefits include clinical guidance, TAVR outcome prediction, device testing
Sophisticated in vivo modeling can enhance device development and therapy testing
Observational findings over 5+ years of follow-up argue for caution in this population
Our experts recap the most notable changes and developments
Advertisement
Advertisement